09:18 AM EST, 02/05/2025 (MT Newswires) -- Hydreight Technologies ( HYDTF ) on Wednesday said its VSDHOne platform now provides Nicotinamide Adenine Dinucleotide (NAD+) therapy through patch, injection, and nasal spray.

"NAD+ therapy has gained significant attention for its role in cellular health and longevity," said Hydreight Technologies ( HYDTF ) Chief Executive Shane Madden. "By integrating NAD+ into our VSDHOne platform, we are making it easier for patients to access this powerful coenzyme in multiple convenient formats, ensuring they can benefit from its potential impact on energy, cognition, and overall wellness."

Shares of the company closed down $0.30 or 12.5%, at $2.10 on Tuesday on the TSX Venture Exchange.